NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 129 filers reported holding NURIX THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $190,424 | -36.8% | 24,227 | -19.6% | 0.40% | -14.4% |
Q2 2023 | $301,119 | +3.0% | 30,142 | -8.5% | 0.47% | +9.1% |
Q1 2023 | $292,454 | -27.9% | 32,934 | -10.8% | 0.43% | -17.4% |
Q4 2022 | $405,469 | -33.6% | 36,928 | -21.3% | 0.52% | -13.8% |
Q3 2022 | $611,000 | -2.1% | 46,915 | -4.7% | 0.60% | +4.5% |
Q2 2022 | $624,000 | -6.2% | 49,217 | +3.7% | 0.57% | +59.0% |
Q1 2022 | $665,000 | -51.4% | 47,464 | +0.4% | 0.36% | -24.0% |
Q4 2021 | $1,369,000 | +13.6% | 47,292 | +17.6% | 0.48% | +17.9% |
Q3 2021 | $1,205,000 | +92.5% | 40,212 | +70.3% | 0.40% | +75.2% |
Q2 2021 | $626,000 | – | 23,611 | – | 0.23% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
AtonRa Partners | 24,227 | $190,424 | 0.40% |
WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |